Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ ) 0.4244 -0.0034 (-0.79%) Streaming Delayed Price Updated: 3:59 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Mainz Biomed N.V. - Ordinary Shares < Previous 1 2 3 4 Next > Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test July 09, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Provides Half Year 2024 Corporate Update July 02, 2024 Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 June 03, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Reports Results of 2024 Annual General Meeting May 31, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting May 28, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial May 20, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. May 07, 2024 The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic April 25, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Reports Full Year 2023 Financial Results April 09, 2024 ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment March 19, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options March 18, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations March 12, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic March 05, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community February 27, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert® February 22, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy February 21, 2024 Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany February 06, 2024 Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert® as a laboratory medical service directly to physicians and patients From Mainz BioMed NV Via GlobeNewswire Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium January 11, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Provides Year-End Corporate Review 2023 January 09, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees December 19, 2023 Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and... From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland December 12, 2023 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers December 05, 2023 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast November 29, 2023 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference November 20, 2023 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 16, 2023 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering November 15, 2023 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering November 13, 2023 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test November 09, 2023 Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing From Mainz BioMed NV Via GlobeNewswire Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA November 07, 2023 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper October 31, 2023 Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test From Mainz BioMed NV Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.